SpringerLink
Log in

Efficacy and Safety of 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Helicobacter pylori Eradication in the Elderly

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background

Aging may affect the efficacy of Helicobacter pylori eradication. The aim of our study was to assess the efficacy and safety of 7-day non-bismuth concomitant quadruple therapy as a first-line H. pylori infection eradication regimen in elderly individuals.

Methods

We retrospectively analyzed a cohort with prospectively collected data from January 2013 to December 2019 at Chang Gung Memorial Hospital in Kaohsiung. There were 408 naive infected subjects aged 20 years or older who were treated with 7 days of concomitant therapy as a first-line H. pylori eradication regimen. We divided the patients into an elderly group (aged ≥ 65 years) and a control group (aged < 65 years). Two patients were lost during follow-up in the elderly group and 29 patients were lost in the control group, resulting in 56 in the ≥ 65-year age group and 321 in the control group. The patients were asked to perform urea breath tests 8 weeks later.

Results

The eradication rates for the elderly and control groups were 93.1% (95% confidence interval (CI): 83.3–98.1) and 84.0% (95% CI 79.7–87.7) (p = 0.070), respectively, in the intention-to-treat analysis, and 96.4% (95% CI 87.6–99.6) and 91.6% (95% CI 88.0–94.4) (p = 0.210), respectively, in the per-protocol (PP) analysis. The adverse event rates were 8.9% in the elderly group and 12.8% in the control group (p = 0.417). The compliance was 100% in both groups. No significant difference was seen in antibiotic resistance in either group. Multivariate analysis revealed that metronidazole resistance (odds ratio (OR) 6.870, 95% CI 1.182–39.919, p = 0.032) and dual-therapy resistance (OR 7.188, 95% CI 1.326–38.952, p = 0.022) were independent factors for eradication failure.

Conclusions

The efficacy of non-bismuth concomitant quadruple therapy in the elderly cohort was comparable with that in the non-elderly cohort for first-line H. pylori eradication with acceptable adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.

    Article  CAS  Google Scholar 

  2. Soenen S, Rayner CK, Jones KL, Horowitz M. The ageing gastrointestinal tract. Curr Opin Clin Nutr Metab Care. 2016;19(1):12–8. https://doi.org/10.1097/MCO.0000000000000238.

    Article  Google Scholar 

  3. Cizginer S, Ordulu Z, Kadayifci A. Approach to Helicobacter pylori infection in geriatric population. World J Gastrointest Pharmacol Ther. 2014;5(3):139–47. https://doi.org/10.4292/wjgpt.v5.i3.139.

    Article  Google Scholar 

  4. Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676–82.

    Article  Google Scholar 

  5. Kong YJ, Yi HG, Dai JC, Wei MX. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2014;20(19):5903–11. https://doi.org/10.3748/wjg.v20.i19.5903.

    Article  Google Scholar 

  6. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144(3):528–35.

    Article  CAS  Google Scholar 

  7. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022. https://doi.org/10.1136/gutjnl-2022-327745.

    Article  Google Scholar 

  8. Tomita N, Mizokami F, Kisara S, Arai H. Transdisciplinary approach for potentially harmful drug-drug interaction detection as a part of a comprehensive medication review and geriatric assessment. Geriatr Gerontol Int. 2019;19(5):462–3.

    Article  Google Scholar 

  9. Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, et al. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter. 2017;22(3): e12368. https://doi.org/10.1111/hel.12368.

    Article  CAS  Google Scholar 

  10. Kao SS, Chen WC, Hsu PI, Lai KH, Yu HC, Cheng HH, et al. 7-day nonbismuth-containing concomitant therapy achieves a high eradication rate for Helicobacter pylori in Taiwan. Gastroenterol Res Pract. 2012. https://doi.org/10.1155/2012/463985.

    Article  Google Scholar 

  11. Tai WC, Liang CM, Lee CH, Chiu CH, Hu ML, Lu LS, et al. Seven-day Nonbismuth containing quadruple therapy could achieve a grade “A” success rate for first-line Helicobacter pylori Eradication. Biomed Res Int. 2015. https://doi.org/10.1155/2015/623732.

    Article  Google Scholar 

  12. Megraud FH. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374–784.

    Article  CAS  Google Scholar 

  13. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori Infection. Clin Gastroenterol Hepatol. 2010;8:36–41.

    Article  CAS  Google Scholar 

  14. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment–a pilot study. Helicobacter. 2012;17(5):374–81.

    Article  CAS  Google Scholar 

  15. Hsu PI, Wu DC, Chen A, et al. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest. 2008;38:404–9.

    Article  CAS  Google Scholar 

  16. Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O, et al. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol. 2002;97:2231–8.

    Article  CAS  Google Scholar 

  17. Gray SF, Wyatt JI, Rathbone BJ. Simplified techniques for identifying Campylobacter pyloridis. J Clin Pathol. 1986;39(11):1279.

    Article  CAS  Google Scholar 

  18. Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, et al. A comparison between dexlansoprazole modified release-based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial. Infect Drug Resist. 2019;12:2923–31.

    Article  CAS  Google Scholar 

  19. The European Committee on Antimicrobial Susceptibility Testing—EUCAST, https://www.eucast.org/clinical_breakpoints (EUCAST Clinical Breakpoint Tables v. 12.0, valid from 2022-01-01.

  20. Lee BE, Kim JS, Kim BW, Kim JH, Kim JI, Chung JW, et al. Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years. Helicobacter. 2021;26(2): e12780.

    Article  CAS  Google Scholar 

  21. Kobayashi S, Joshita S, Yamamoto C, Yanagisawa T, Miyazawa T, Miyazawa M, et al. Efficacy and safety of eradication therapy for elderly patients with Helicobacter pylori infection. Medicine (Baltimore). 2019;98(30):e16619. https://doi.org/10.1097/MD.0000000000016619.

    Article  CAS  Google Scholar 

  22. Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, et al. Primary Helicobacter pylori resistance in elderly patients over 20 years: a Bulgarian study. Diagn Microbiol Infect Dis. 2017;88(3):264–7. https://doi.org/10.1016/j.diagmicrobio.2017.05.001.

    Article  Google Scholar 

  23. Lyu T, Cheung KS, Ni L, Guo J, Mu P, Li Y, et al. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort study. J Antimicrob Chemother. 2020;75(11):3391–4.

    Article  Google Scholar 

  24. Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, et al. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol. 2020;10(13):1756284820976990. https://doi.org/10.1177/1756284820976990.

    Article  CAS  Google Scholar 

  25. Chuah SK, Liang CM, Lee CH, Chiou SS, Chiu YC, Hu ML, et al. A randomized control trial comparing 2 levofloxacin-containing second-line therapies for Helicobacter pylori eradication. Medicine (Baltimore). 2016;95: e3586.

    Article  CAS  Google Scholar 

  26. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343–57.

    Article  CAS  Google Scholar 

  27. Moon JY, Kim GH, You HS, Lee BE, Ryu DY, Cheong JH, et al. Levofloxacin, metronidazole, and lansoprazole triple therapy compared to quadruple therapy as a second-line treatment of Helicobacter pylori Infection in Korea. Gut and liver. 2013;7(4):406–10.

    Article  CAS  Google Scholar 

  28. Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, et al. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis. Helicobacter. 2020;25(4): e12714.

    Article  CAS  Google Scholar 

  29. Xu H, Wang W, Ma X, Feng R, Su Y, Cheng L, et al. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(6):775–86.

    Article  CAS  Google Scholar 

  30. Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74(6):1718–24. https://doi.org/10.1093/jac/dkz046.

    Article  CAS  Google Scholar 

  31. Durazzo M, Ferro A, Fagoonee S, Staiano MT, Saracco GM, Pellicano R. Helicobacter pylori eradication with a clarithromycin-based triple therapy in elderly patients. Panminerva Med. 2021;63(3):332–5. https://doi.org/10.23736/S0031-0808.21.04500-6.

    Article  Google Scholar 

  32. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther. 2005;21(12):1419–24. https://doi.org/10.1111/j.1365-2036.2005.02519.x.

    Article  CAS  Google Scholar 

  33. Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, et al. Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J. 2017;19(1):298–312. https://doi.org/10.1208/s12248-016-0009-9.

    Article  CAS  Google Scholar 

  34. Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori infection in geriatric patients: current situation and treatment regimens. Front Med (Lausanne). 2021;30(8): 713908. https://doi.org/10.3389/fmed.2021.713908.

    Article  Google Scholar 

  35. Goossens H, Glupczynski Y, Burette A, Van den Borre C, DePrez C, Bodenmann J, et al. Evaluation of a commercially available complement fixation test for diagnosis of Helicobacter pylori infection and for follow-up after antimicrobial therapy. J Clin Microbiol. 1992;30(12):3230–3. https://doi.org/10.1128/jcm.30.12.3230-3233.1992.

    Article  CAS  Google Scholar 

  36. Perets TT, Gingold-Belfer R, Leibovitzh H, Itskoviz D, Schmilovitz-Weiss H, et al. Optimization of 13 C-urea breath test threshold levels for the detection of Helicobacter pylori infection in a national referral laboratory. J Clin Lab Anal. 2019;33(2): e22674. https://doi.org/10.1002/jcla.22674.

    Article  CAS  Google Scholar 

  37. Kwon YH, Kim N, Yoon H, Shin CM, Park YS, Lee DH. Effect of citric acid on accuracy of 13C-urea breath test after Helicobacter pylori eradication therapy in a region with a high prevalence of atrophic gastritis. Gut Liver. 2019;13(5):506–14. https://doi.org/10.5009/gnl18398.

    Article  CAS  Google Scholar 

  38. Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med. 2015;3(1):9. https://doi.org/10.3978/j.issn.2305-5839.2014.12.04.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Fu Jen Catholic University Hospital, New Taipei City, Taipei, Taiwan

    Te-Ling Ma

  2. Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao-Sung Dist. 833, Kaohsiung City, Taiwan

    Wei-Chen Tai, Chih-Chien Yao, Chih-Ming Liang & Seng-Kee Chuah

  3. Chang Gung University College of Medicine, Taoyuan City, Taiwan

    Wei-Chen Tai, Chih-Ming Liang & Seng-Kee Chuah

  4. Division of Family Physician, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

    Song-Seng Loke

Authors
  1. Te-Ling Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei-Chen Tai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Song-Seng Loke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chih-Chien Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chih-Ming Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seng-Kee Chuah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chih-Ming Liang.

Ethics declarations

Conflicts of interest

T-LM, W-CT, S-SL, C-CY, C-ML, S-KC declare that they have no commercial association, such as consultancies, stock ownership or other equity interests or patent-licensing arrangements.

Funding

No external funding was used in the conduct of this study or the preparation of this manuscript.

Author contributions

S-K Chuah and C-M Liang participated in the design of the study, coordinated the study, and performed the statistical analysis. T-L Ma wrote the manuscript. S-S Loke, C-C Yao, and W-C Tai contributed with administrative, technical, and/or material support. All authors have read and approved the manuscript.

Data availability statement

The data that support the findings of this study are available from the corresponding author on request. The data are not publicly available due to privacy or ethical restrictions.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Code availability

Not applicable.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, TL., Tai, WC., Loke, SS. et al. Efficacy and Safety of 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Helicobacter pylori Eradication in the Elderly. Drugs Aging 40, 71–79 (2023). https://doi.org/10.1007/s40266-022-00990-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-022-00990-7

Search

Navigation